• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

根治性手术后胸段食管鳞癌淋巴结复发患者行放疗或同步放化疗。

Radiotherapy with or without concurrent chemotherapy for lymph node recurrence after radical surgery of thoracic esophageal squamous cell carcinoma.

机构信息

Department of Radiotherapy, Jiangsu Cancer Hospital, Nanjing, China.

出版信息

Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):710-4. doi: 10.1016/j.ijrobp.2009.08.065. Epub 2010 Feb 19.

DOI:10.1016/j.ijrobp.2009.08.065
PMID:20172661
Abstract

PURPOSE

To retrospectively compare the outcomes of patients with lymph node recurrence after radical surgery of esophageal cancer, when given radiotherapy with or without concurrent chemotherapy.

METHODS AND MATERIALS

Between January 1996 and December 2005, the data from 73 patients with lymph node recurrence after radical surgery of thoracic esophageal squamous cell carcinoma were retrospectively reviewed. The patients were separated into two groups: radiochemotherapy (RC, 31 patients) and radiotherapy alone (RA, 42 patients). Patients in the RC group received at least two cycles of 5-fluorouracil/cisplatin chemotherapy concurrently with radiotherapy.

RESULTS

The median duration of follow-up was 11 months (range, 2-48). The overall survival rate for all patients was 46.7% and 4.7% at 1 and 3 years, respectively. The median overall survival time was 9 months (95% confidence interval, 6.96-11.04) and 17 months (95% confidence interval, 13.61-20.39) for RA and RC groups, respectively. The survival rate at 1 and 3 years was 62.5% and 10.5% in the RC group and 33.8% and 0% in the RA group (p = .0049, log-rank test; hazard ratio for death, 0.52; 95% confidence interval, 0.30-0.92). Acute toxicities were more frequent in the RC group than in the RA group. No significant differences were found in the late toxicity profiles between the two groups.

CONCLUSION

The results of the present retrospective analysis suggest that RC should be considered an effective and well-tolerated treatment of patients with thoracic esophageal squamous cell carcinoma and postoperative lymph node recurrence.

摘要

目的

回顾性比较根治性手术后食管癌淋巴结复发患者接受放疗联合或不联合同期化疗的结果。

方法和材料

1996 年 1 月至 2005 年 12 月,回顾性分析 73 例胸段食管鳞癌根治术后淋巴结复发患者的资料。患者分为两组:放化疗组(RC 组,31 例)和单纯放疗组(RA 组,42 例)。RC 组患者至少接受两个周期的氟尿嘧啶/顺铂化疗联合放疗。

结果

中位随访时间为 11 个月(范围,2-48)。所有患者的总生存率分别为 46.7%和 4.7%,1 年和 3 年。RA 组和 RC 组的中位总生存时间分别为 9 个月(95%置信区间,6.96-11.04)和 17 个月(95%置信区间,13.61-20.39)。RC 组 1 年和 3 年的生存率分别为 62.5%和 10.5%,RA 组分别为 33.8%和 0%(p =.0049,log-rank 检验;死亡风险比为 0.52;95%置信区间,0.30-0.92)。RC 组的急性毒性比 RA 组更常见。两组的晚期毒性谱无显著差异。

结论

本回顾性分析结果表明,RC 应被视为治疗胸段食管鳞癌根治术后淋巴结复发患者的有效且耐受良好的治疗方法。

相似文献

1
Radiotherapy with or without concurrent chemotherapy for lymph node recurrence after radical surgery of thoracic esophageal squamous cell carcinoma.根治性手术后胸段食管鳞癌淋巴结复发患者行放疗或同步放化疗。
Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):710-4. doi: 10.1016/j.ijrobp.2009.08.065. Epub 2010 Feb 19.
2
Clinical benefit of chemosensitivity test for patients with regional lymph node-positive esophageal squamous cell carcinoma.区域淋巴结阳性食管鳞状细胞癌患者化疗敏感性试验的临床益处。
J Surg Oncol. 2003 Sep;84(1):10-6. doi: 10.1002/jso.10286.
3
Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma.食管鳞状细胞癌根治性放化疗后局部失败患者挽救性内镜黏膜切除术的长期结果
Endoscopy. 2008 Sep;40(9):717-21. doi: 10.1055/s-2008-1077480. Epub 2008 Sep 4.
4
The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma.手术及术后放化疗在淋巴结阳性食管癌患者中的作用。
Cancer. 2001 Jun 15;91(12):2423-30.
5
[A prospective study of combined chemoradiotherapy followed by surgery in the treatment of esophageal carcinoma].食管癌同步放化疗后手术治疗的前瞻性研究
Zhonghua Zhong Liu Za Zhi. 2003 Jul;25(4):376-9.
6
Influence of number of metastatic lymph nodes on survival of curative resected thoracic esophageal cancer patients and value of radiotherapy: report of 549 cases.转移性淋巴结数量对根治性切除的胸段食管癌患者生存的影响及放疗价值:549例报告
Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):82-90. doi: 10.1016/j.ijrobp.2004.08.046.
7
Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer.长期给予低剂量顺铂联合5-氟尿嘧啶可延长食管癌患者术后生存期。
Oncol Rep. 2005 Apr;13(4):667-72.
8
[Prospective non-randomized study of chemotherapy combined with radiotherapy versus chemotherapy alone in patients with metastatic or relapsed esophageal squamous cell carcinoma].转移性或复发性食管鳞状细胞癌患者化疗联合放疗与单纯化疗的前瞻性非随机研究
Zhonghua Zhong Liu Za Zhi. 2007 Jun;29(6):474-7.
9
A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).一项比较术后顺铂联合氟尿嘧啶辅助化疗与术前化疗治疗局部晚期食管鳞状细胞癌(JCOG9907)的随机临床试验。
Ann Surg Oncol. 2012 Jan;19(1):68-74. doi: 10.1245/s10434-011-2049-9. Epub 2011 Aug 31.
10
Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus.可切除食管鳞状细胞癌单纯手术与放化疗联合选择性手术的前瞻性比较。
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):348-56. doi: 10.1016/j.ijrobp.2009.02.086.

引用本文的文献

1
Radiotherapy combined with anlotinib in locoregional recurrent esophageal squamous cell carcinoma after radical surgery: a prospective, Phase II clinical trial.放疗联合安罗替尼治疗根治性手术后局部区域复发的食管鳞状细胞癌:一项前瞻性II期临床试验。
Br J Cancer. 2025 Jul 16. doi: 10.1038/s41416-025-03101-6.
2
Radiotherapy and chemoradiotherapy for postoperative recurrence in patients with esophageal squamous cell carcinoma.术后复发食管癌患者的放化疗。
Cancer Med. 2024 Aug;13(16):e70108. doi: 10.1002/cam4.70108.
3
Outcomes of solitary postoperative recurrence of esophageal squamous cell carcinoma diagnosed with FDG-PET/CT and treated with definitive radiation therapy.
孤立性术后复发食管鳞癌的 FDG-PET/CT 诊断和根治性放疗疗效。
Esophagus. 2023 Jul;20(3):548-556. doi: 10.1007/s10388-023-01000-4. Epub 2023 Apr 7.
4
Clinical outcomes of salvage radiotherapy in patients with supraclavicular lymph node metastases after esophagectomy.食管癌切除术后锁骨上淋巴结转移患者挽救性放疗的临床结局
Front Oncol. 2023 Jan 11;12:1016150. doi: 10.3389/fonc.2022.1016150. eCollection 2022.
5
Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma.挽救性同期放化疗(三维适形放疗联合氟尿嘧啶/铂类化疗)治疗食管鳞癌术后区域性复发的疗效和生存结果。
Esophagus. 2022 Oct;19(4):645-652. doi: 10.1007/s10388-022-00936-3. Epub 2022 Jul 28.
6
Outcomes and Prognostic Factors of Salvage Radiation for Postoperative Lymph Node Recurrence of Esophageal Squamous Cell Carcinoma.食管鳞状细胞癌术后淋巴结复发挽救性放疗的疗效及预后因素
Front Oncol. 2021 Mar 19;11:638521. doi: 10.3389/fonc.2021.638521. eCollection 2021.
7
Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: a prospective, multicenter clinical trial protocol.根治性手术或姑息性手术后复发食管癌患者挽救性放化疗:一项前瞻性、多中心临床试验方案。
BMC Cancer. 2020 Sep 14;20(1):877. doi: 10.1186/s12885-020-07315-0.
8
Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma.胸段食管鳞癌患者术后复发模式及复发后挽救性治疗的疗效。
BMC Cancer. 2020 Feb 22;20(1):144. doi: 10.1186/s12885-020-6622-0.
9
Weekly Chemotherapy of 5-Fluorouracil plus Cisplatin Concurrent with Radiotherapy for Esophageal Squamous Cell Carcinoma Patients with Postoperative Locoregional Recurrence: Results from a Phase II Study.每周氟尿嘧啶和顺铂化疗联合放疗治疗食管癌术后局部区域复发患者:来自 II 期研究的结果。
Oncologist. 2020 Apr;25(4):308-e625. doi: 10.1634/theoncologist.2019-0931. Epub 2019 Dec 27.
10
Recurrence and prognostic model for identifying patients at risk for esophageal cancer after surgery.用于识别食管癌术后高危患者的复发及预后模型。
Cancer Manag Res. 2018 Nov 21;10:6109-6120. doi: 10.2147/CMAR.S186194. eCollection 2018.